Summary

The global vascular stent market is projected to reach USD 15.6 billion by 2029 from USD 11.4 billion in 2024, at a CAGR of 6.5% from 2024 to 2029. The growth of the market is driven by increase in acquisitions by major players, increase in adoption of minimally invasive procedures. However, availability of alternative treatment methods to treat vascular disease, is impacting the growth of the market. Moreover, the product recalls and failures in the field of vascular stent are a major factor restraining the market growth.
“Polymer segment to witness the significant growth during the forecast period.”
Based on material, the segment is divided into metallic material, and polymer material. The polymer segment is further divided into biodegradable polymers and non-biodegradable polymers. In 2023, among these two polymers, the biodegradable polymer segment to witness the highest growth in vascular stent market. Because of their prospective medicinal uses, biodegradable polymers are expected to witness significant expansion in the vascular stent market. These polymers, which are essential for drug-eluting stent (DES) platforms, guarantee the antiproliferative medications' optimum release, leading to the best possible DES performance. Compared to permanent polymers, biodegradable polymers can reduce chronic inflammation of the arterial wall, hence reducing the risk of late restenosis and stent thrombosis. Clinical experiments have demonstrated that biodegradable polymer DES platforms function similarly to permanent polymer DES platforms during the first year of implantation, with longer-term follow-ups revealing encouragingly lower rates of stent thrombosis. The promise to increase patient safety and efficacy is what motivates their planned market expansion.
“Peripheral segment accounted for the significant growth in the vascular stent market during the forecast period.”
Based on product, the vascular stent market is segmented into coronary stents, peripheral stents, and EVAR stent grafts. Among these in 2023, peripheral stents accounted for significant share. Throughout the projected period, peripheral stents are anticipated to have substantial growth in the vascular stent market, driven by the increased prevalence of peripheral vascular illnesses, especially in the aging population. The American Heart Association revealed in June 2023 that 200 million people worldwide and approximately 12 million Americans suffer with peripheral vascular disease (PAD). This rising prevalence highlights the need for efficient treatment alternatives such as Stents for the periphery. Additionally, developments in biodegradable polymer stents provide a more patient-centered, minimally invasive approachable substitute, increasing their uptake and market expansion even more.
“APAC is estimated to register the highest CAGR during the forecast period.”
In this report, the vascular stent market is segmented into five major regional segments, namely, North America, Europe, Asia Pacific, Latin America and Middle East and Africa. During the forecast period, the Asia Pacific region is anticipated to experience the largest growth in the vascular stent market by material, mainly because of the increasingly aging population that is causing an increase in the frequency of cardiovascular illnesses. As of June 2022, the population of Asia and the Pacific is aging at a rate faster than any other region in the world, with 630 million people in the region making up 60% of the world's senior population, according to the Economic and Social Commission for Asia and the Pacific. By 2050, it is anticipated that this number would increase to 1.3 billion, greatly increasing the need for vascular stents to treat age-related cardiovascular diseases and propelling market expansion.

Breakdown of supply-side primary interviews, by company type, designation, and region:
• By Company Type: Tier 1 (20%), Tier 2 (45%), and Tier 3 (35%)
• By Designation: C-level (30%), Director-level (20%), and Others (50%)
• By Region: North America (35%), Europe (24%), Asia Pacific (25%), RoW (16%)
List of Companies Profiled in the Report
o Medtronic Plc (Ireland)
o Abbott Laboratories (US)
o Boston Scientific Corporation (US)
o B Braun SE (Germany)
o Terumo Corporation (Japan)
o Biotronik SE & Co.KG (Germany)
o Shanghai Microport Medical (Group) Co., Ltd (China)
o Meril Life Science Pvt. Ltd (India)
o Sahajanan Medical Technologies Limited (India)
o Becton, Dickinson, and Company (US)
o W.L. Gore & Associates, Inc (US)
o Cordis Corporation (US)
o Artivion Inc (US)
o Stryker Corporation (US)
o LifeTech Scientific Corporation (China)
o Translumina (Germany)
o Lepu Medical Technology (Beijing) Co., Ltd (China)
o Endologix LLC. (US)
o Biosensors International Group, Ltd (Singapore)
o Cook Medical (US)
o Insitu Technologies Inc (US)
o iVascular (Spain)
o OrbusNeich Medical Group Holdings Limited (China)
o Alvimedica (Turkey).
o Elixir Medical (US)

Research Coverage
This report studies the vascular stent market based on product, procedure, technology, application, end user and region. The report also analyses factors (such as drivers, restraints, opportunities and challenges) affecting market growth. It evaluates the opportunities and challenges in the market for stakeholders and provides details of the competitive landscape for market leaders. The report also studies micro markets with respect to their growth trends, prospects, and contributions to the total vascular stent market. The report forecasts the revenue of the market segments with respect to five major regions.
Reasons to Buy the Report
This report also includes.
• Analysis of key drivers (rising incidence of vascular diseases and growth in number of angioplasty procedures, advancements in stent technology and materials, increase in adoption of minimally invasive procedures),restraints (Availability of alternative treatment methods for vascular diseases, stringent regulations for product approval, product failures and recalls), challenges (High risk of complications, declining cost of stent), opportunities (Development of bioresorbable vascular scaffold stent, emerging markets to offer high-growth opportunities for market participants, increase in aging population) contributing the growth of the vascular stent market.
• Product Development/Innovation: Detailed insights on upcoming trends, research & development activities, and new software launches in the vascular stent market.
• Market Development: Comprehensive information on the lucrative emerging markets, technology, product, mode of delivery, material, end-user and region.
• Market Diversification: Exhaustive information about the growing geographies, recent developments, investments in the vascular stent market.
• Competitive Assessment: In-depth assessment of market shares, growth strategies, product offerings, company evaluation quadrant, and capabilities of leading players in the global vascular stent market.

ページTOPに戻る

Table of Contents

1 INTRODUCTION 37
1.1 STUDY OBJECTIVES 37
1.2 MARKET DEFINITION 37
1.3 MARKET SCOPE 38
1.3.1 MARKETS COVERED 38
1.3.2 INCLUSIONS & EXCLUSIONS 39
1.3.3 YEARS CONSIDERED 39
1.3.4 CURRENCY CONSIDERED 40
1.4 MARKET STAKEHOLDERS 40
1.5 SUMMARY OF CHANGES 40
2 RESEARCH METHODOLOGY 42
2.1 RESEARCH DATA 42
2.1.1 SECONDARY DATA 43
2.1.1.1 Key data from secondary sources 44
2.1.2 PRIMARY DATA 44
2.1.2.1 Key data from primary sources 46
2.1.2.2 Key industry insights 47
2.2 MARKET SIZE ESTIMATION 48
2.3 MARKET BREAKDOWN & DATA TRIANGULATION 53
2.4 MARKET RANKING ANALYSIS 53
2.5 STUDY ASSUMPTIONS 54
2.6 RESEARCH LIMITATIONS 54
2.6.1 METHODOLOGY-RELATED LIMITATIONS 54
2.6.2 SCOPE-RELATED LIMITATIONS 54
2.7 RISK ASSESSMENT 55
3 EXECUTIVE SUMMARY 56
4 PREMIUM INSIGHTS 62
4.1 VASCULAR STENTS MARKET OVERVIEW 62
4.2 NORTH AMERICA: VASCULAR STENTS MARKET, BY PRODUCT 63
4.3 GEOGRAPHIC SNAPSHOT OF VASCULAR STENTS MARKET 64
4.4 VASCULAR STENTS MARKET: REGIONAL MIX, 2024–2029 (USD MILLION) 65
 
5 MARKET OVERVIEW 66
5.1 INTRODUCTION 66
5.2 MARKET DYNAMICS 66
5.2.1 DRIVERS 67
5.2.1.1 Increasing incidence of vascular diseases and subsequent rise in angioplasty procedures 67
5.2.1.2 Technological advancements in stents 67
5.2.1.3 Growing preference for minimally invasive surgeries 68
5.2.2 RESTRAINTS 68
5.2.2.1 Availability of open surgical procedures to hinder market growth 68
5.2.2.2 Stringent regulatory guidelines for product approval 68
5.2.2.3 Product failures and recalls 69
5.2.3 OPPORTUNITIES 69
5.2.3.1 Development of bioresorbable vascular scaffold stents 69
5.2.3.2 High growth potential of emerging markets 70
5.2.4 CHALLENGES 70
5.2.4.1 Complications associated with stenting procedures 70
5.2.4.2 Declining cost of stents 71
5.3 INDUSTRY TRENDS 71
5.3.1 COMBINATION THERAPIES 71
5.3.2 PERSONALIZED MEDICINE 72
5.3.3 EXPANDING APPLICATIONS 72
5.4 TECHNOLOGY ANALYSIS 72
5.4.1 KEY TECHNOLOGIES 72
5.4.1.1 3D printing 72
5.4.1.2 Electrospinning 73
5.4.1.3 Balloon-expandable stents 73
5.4.2 COMPLEMENTARY TECHNOLOGIES 73
5.4.2.1 Element simulation technology 73
5.4.2.2 Stereolithography (SLA) technology 74
5.4.2.3 Laser-cutting technology 74
5.4.3 ADJACENT TECHNOLOGIES 74
5.4.3.1 Continuous sinusoid technology 75
5.4.3.2 Micro-injection molding technology 75
5.4.3.3 Imaging technology 75
5.5 PORTER’S FIVE FORCE ANALYSIS 76
5.5.1 INTENSITY OF COMPETITIVE RIVALRY 76
5.5.2 BARGAINING POWER OF SUPPLIERS 76
5.5.3 BARGAINING POWER OF BUYERS 77
5.5.4 THREAT OF SUBSTITUTES 77
5.5.5 THREAT OF NEW ENTRANTS 77
 
5.6 REGULATORY LANDSCAPE 78
5.6.1 REGULATORY ANALYSIS 78
5.6.1.1 North America 78
5.6.1.1.1 US 78
5.6.1.1.2 Canada 78
5.6.1.2 Europe 78
5.6.1.3 Asia Pacific 79
5.6.1.3.1 Japan 79
5.6.1.3.2 China 79
5.6.1.4 Latin America 80
5.6.1.5 Middle East & Africa 80
5.6.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 80
5.7 PATENT ANALYSIS 83
5.7.1 PATENT PUBLICATION TRENDS IN VASCULAR STENTS MARKET 83
5.7.2 INSIGHTS: JURISDICTION AND TOP APPLICANT ANALYSIS 83
5.8 TRADE ANALYSIS 86
5.8.1 TRADE ANALYSIS FOR VASCULAR STENTS 86
5.9 PRICING ANALYSIS 87
5.10 KEY CONFERENCES & EVENTS 88
5.11 KEY STAKEHOLDERS AND BUYING CRITERIA 89
5.11.1 KEY STAKEHOLDERS IN BUYING PROCESS 89
5.11.2 BUYING CRITERIA 89
5.12 UNMET NEEDS 90
5.13 END-USER EXPECTATIONS 91
5.14 IMPACT OF GENERATIVE AI ON VASCULAR STENTS MARKET 91
5.15 ECOSYSTEM ANALYSIS 92
5.16 CASE STUDY ANALYSIS 93
5.16.1 CASE STUDY 1: UTILIZATION OF GORE VIABAHN VBX BALLOON-EXPANDABLE STENTS FOR ANGIOGRAPHY PROCEDURE 93
5.16.2 CASE STUDY 2: SUCCESSFUL TREATMENT OF PATIENT WITH SEVERE CAROTID ARTERY STENOSIS 94
5.16.3 CASE STUDY 3: W.L. GORE UTILIZED VBX BALLOON-EXPANDABLE STENT FOR ILIAC ARTERY STENOSIS TREATMENT 95
5.17 SUPPLY CHAIN ANALYSIS 95
5.18 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 97
5.19 INVESTMENT & FUNDING SCENARIO 97
5.20 ADJACENT MARKET ANALYSIS 98
5.20.1 INTERVENTIONAL CARDIOLOGY DEVICES MARKET 98
 
6 VASCULAR STENT MARKET, BY TECHNOLOGY 100
6.1 INTRODUCTION 101
6.2 DRUG-ELUTING STENTS 102
6.2.1 LONG-TERM BENEFITS ASSOCIATED WITH DRUG-ELUTING STENTS TO DRIVE MARKET 102
6.3 BARE METAL STENTS 104
6.3.1 COST-EFFICIENT BENEFITS TO FUEL UPTAKE 104
6.4 COVERED STENTS 107
6.4.1 UTILIZATION IN ENDOVASCULAR REPAIR AND VASCULAR LESIONS TO DRIVE MARKET 107
6.5 BIOABSORBABLE STENTS 110
6.5.1 ABILITY TO MINIMIZE COMPLICATIONS ASSOCIATED WITH PERMANENT DEVICES TO SUPPORT MARKET GROWTH 110
7 VASCULAR STENTS MARKET, BY PRODUCT 113
7.1 INTRODUCTION 114
7.2 CORONARY STENTS 114
7.2.1 INCREASING PREVALENCE OF CORONARY ARTERY DISEASE TO PROPEL MARKET 114
7.3 PERIPHERAL STENTS 116
7.3.1 CAROTID ARTERY STENTS 119
7.3.1.1 Rapid recovery time and lower risk of myocardial ischemia to boost demand 119
7.3.2 FEMORAL ARTERY STENTS 121
7.3.2.1 Minimal incisions and shorter recovery time to fuel market 121
7.3.3 RENAL ARTERY STENTS 123
7.3.3.1 Rising incidence of hypertension and FMD to support market growth 123
7.3.4 ILIAC ARTERY STENTS 125
7.3.4.1 Increasing prevalence of atherosclerosis to fuel uptake 125
7.3.5 OTHER PERIPHERAL STENTS 127
7.4 EVAR STENT GRAFTS 129
7.4.1 ABDOMINAL AORTIC ANEURYSM STENT GRAFTS 130
7.4.1.1 Rising incidence of AAA cases to drive market 130
7.4.2 THORACIC AORTIC ANEURYSM STENT GRAFTS 132
7.4.2.1 Rising prevalence of renal artery stenosis to support market growth 132
8 VASCULAR STENTS MARKET, BY MODE OF DELIVERY 135
8.1 INTRODUCTION 136
8.2 BALLOON-EXPANDABLE STENTS 136
8.2.1 ABILITY TO TREAT CORONARY VESSEL DAMAGE TO DRIVE MARKET 136
8.3 SELF-EXPANDING STENTS 139
8.3.1 HIGH UPTAKE IN ABDOMINAL & THORACIC EVAR PROCEDURES TO PROPEL MARKET 139
9 VASCULAR STENTS MARKET, BY MATERIAL 143
9.1 INTRODUCTION 144
9.2 METALLIC MATERIALS 144
9.2.1 COBALT CHROMIUM 147
9.2.1.1 Biocompatibility properties to boost demand 147
9.2.2 PLATINUM CHROMIUM 149
9.2.2.1 Enhanced visibility and superior radial strength to support market growth 149
9.2.3 NICKEL TITANIUM 151
9.2.3.1 Growing adoption of MIS procedures to boost demand 151
9.2.4 STAINLESS STEEL 153
9.2.4.1 High reliability and cost-efficiency to boost uptake 153
9.3 POLYMERIC MATERIALS 155
9.3.1 BIODEGRADABLE POLYMERS 158
9.3.1.1 Advantages offered by biodegradable polymers to drive market 158
9.3.2 NON-BIODEGRADABLE POLYMERS 160
9.3.2.1 Inert alternative to potential inflammatory responses to support market growth 160
10 VASCULAR STENTS MARKET, BY END USER 163
10.1 INTRODUCTION 164
10.2 HOSPITALS 164
10.2.1 RISING NUMBER OF ANGIOPLASTY PROCEDURES TO FUEL MARKET 164
10.3 CARDIAC CENTERS 166
10.3.1 INCREASING CASES OF STROKE TO DRIVE MARKET 166
11 VASCULAR STENTS MARKET, BY REGION 169
11.1 INTRODUCTION 170
11.2 NORTH AMERICA 172
11.2.1 NORTH AMERICA: MACROECONOMIC OUTLOOK 173
11.2.2 US 181
11.2.2.1 Supportive regulatory policies for cardiovascular product commercialization to fuel uptake 181
11.2.3 CANADA 188
11.2.3.1 Rising incidence of peripheral artery disease to drive market 188
11.3 EUROPE 194
11.3.1 EUROPE: MACROECONOMIC OUTLOOK 195
11.3.2 GERMANY 202
11.3.2.1 Rising uptake of angioplasty procedures to fuel market 202
11.3.3 UK 209
11.3.3.1 Increasing incidence of acute coronary syndrome to propel market 209
11.3.4 FRANCE 215
11.3.4.1 Rising incidence of chronic diseases to drive market 215
11.3.5 ITALY 222
11.3.5.1 Rising cases of atherosclerotic CVD to support market growth 222
11.3.6 SPAIN 228
11.3.6.1 Increasing prevalence of obesity to boost demand 228
11.3.7 REST OF EUROPE 234
11.4 ASIA PACIFIC 241
11.4.1 ASIA PACIFIC: MACROECONOMIC OUTLOOK 241
11.4.2 CHINA 250
11.4.2.1 Growing demand for peripheral artery stents to drive market 250
11.4.3 JAPAN 256
11.4.3.1 Increasing preference for PCI surgeries to drive market 256
11.4.4 INDIA 263
11.4.4.1 Improvements in healthcare policies for affordable medical devices to propel market 263
11.4.5 AUSTRALIA 270
11.4.5.1 Rising hospitalization rates due to CAD cases to drive market 270
11.4.6 SOUTH KOREA 277
11.4.6.1 Rising incidence of diabetes to boost demand 277
11.4.7 REST OF ASIA PACIFIC 283
11.5 LATIN AMERICA 290
11.5.1 LATIN AMERICA: MACROECONOMIC OUTLOOK 290
11.5.2 BRAZIL 297
11.5.2.1 Growing demand for advanced medical equipment to drive market 297
11.5.3 MEXICO 304
11.5.3.1 Increasing imports of medical devices to fuel market 304
11.5.4 REST OF LATIN AMERICA 310
11.6 MIDDLE EAST & AFRICA 317
11.6.1 MIDDLE EAST & AFRICA: MACROECONOMIC OUTLOOK 317
11.6.2 GCC COUNTRIES 324
11.6.2.1 Increasing prevalence of hypertension to drive market 324
11.6.3 REST OF MIDDLE EAST & AFRICA 330
12 COMPETITIVE LANDSCAPE 337
12.1 OVERVIEW 337
12.2 KEY PLAYER STRATEGY/RIGHT TO WIN 337
12.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN VASCULAR STENTS MARKET 337
12.3 REVENUE ANALYSIS 338
12.4 MARKET SHARE ANALYSIS 339
12.4.1 RANKING OF KEY MARKET PLAYERS 341
12.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023 342
12.5.1 STARS 342
12.5.2 EMERGING LEADERS 342
12.5.3 PERVASIVE PLAYERS 342
12.5.4 PARTICIPANTS 342
12.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023 344
12.5.5.1 Company footprint 344
12.5.5.2 Technology footprint 345
12.5.5.3 Product footprint 346
12.5.5.4 Mode of delivery footprint 347
12.5.5.5 Material footprint 348
12.5.5.6 End-user footprint 349
12.5.5.7 Region footprint 350
12.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023 351
12.6.1 PROGRESSIVE COMPANIES 351
12.6.2 RESPONSIVE COMPANIES 351
12.6.3 DYNAMIC COMPANIES 351
12.6.4 STARTING BLOCKS 351
12.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023 353
12.7 COMPANY VALUATION & FINANCIAL METRICS 354
12.7.1 FINANCIAL METRICS 354
12.7.2 COMPANY VALUATION 354
12.8 BRAND/PRODUCT COMPARISON 355
12.9 COMPETITIVE SCENARIO 356
12.9.1 PRODUCT LAUNCHES & APPROVALS 356
12.9.2 DEALS 357
12.9.3 OTHER DEVELOPMENTS 357
13 COMPANY PROFILES 358
13.1 KEY PLAYERS 358
13.1.1 MEDTRONIC PLC 358
13.1.1.1 Business overview 358
13.1.1.2 Products offered 359
13.1.1.3 Recent developments 361
13.1.1.3.1 Product approvals 361
13.1.1.4 MnM view 361
13.1.1.4.1 Key strengths 361
13.1.1.4.2 Strategic choices 362
13.1.1.4.3 Weaknesses & competitive threats 362
13.1.2 ABBOTT LABORATORIES 363
13.1.2.1 Business overview 363
13.1.2.2 Products offered 364
13.1.2.3 Recent developments 366
13.1.2.3.1 Deals 366
 
13.1.2.4 MnM view 366
13.1.2.4.1 Key strengths 366
13.1.2.4.2 Strategic choices 366
13.1.2.4.3 Weaknesses & competitive threats 366
13.1.3 BOSTON SCIENTIFIC CORPORATION 367
13.1.3.1 Business overview 367
13.1.3.2 Products offered 368
13.1.3.3 Recent developments 370
13.1.3.3.1 Deals 370
13.1.3.4 MnM view 371
13.1.3.4.1 Key strengths 371
13.1.3.4.2 Strategic choices 371
13.1.3.4.3 Weaknesses & competitive threats 371
13.1.4 B. BRAUN SE 372
13.1.4.1 Business overview 372
13.1.4.2 Products offered 373
13.1.4.3 MnM view 374
13.1.4.3.1 Key strengths 374
13.1.4.3.2 Strategic choices 374
13.1.4.3.3 Weaknesses & competitive threats 374
13.1.5 TERUMO CORPORATION 375
13.1.5.1 Business overview 375
13.1.5.2 Products offered 376
13.1.5.3 Recent developments 378
13.1.5.3.1 Product approvals 378
13.1.5.4 MnM view 378
13.1.5.4.1 Key strengths 378
13.1.5.4.2 Strategic choices 378
13.1.5.4.3 Weaknesses & competitive threats 378
13.1.6 BIOTRONIK SE & CO. KG. 379
13.1.6.1 Business overview 379
13.1.6.2 Products offered 379
13.1.7 SHANGHAI MICROPORT MEDICAL (GROUP) CO., LTD. 380
13.1.7.1 Business overview 380
13.1.7.2 Products offered 382
13.1.7.3 Recent developments 384
13.1.7.3.1 Product launches & approvals 384
13.1.8 MERIL LIFE SCIENCES PVT. LTD. 386
13.1.8.1 Business overview 386
13.1.8.2 Products offered 386
 
13.1.9 SAHAJANAND MEDICAL TECHNOLOGIES LIMITED 388
13.1.9.1 Business overview 388
13.1.9.2 Products offered 388
13.1.10 BECTON, DICKINSON AND COMPANY 390
13.1.10.1 Business overview 390
13.1.10.2 Products offered 391
13.1.11 W. L. GORE & ASSOCIATES, INC. 393
13.1.11.1 Business overview 393
13.1.11.2 Products offered 393
13.1.11.3 Recent developments 394
13.1.11.3.1 Product launches & approvals 394
13.1.12 CORDIS CORPORATION (SUBSIDIARY OF HELLMAN & FRIEDMAN LLC) 395
13.1.12.1 Business overview 395
13.1.12.2 Products offered 395
13.1.12.3 Recent developments 396
13.1.12.3.1 Product approvals 396
13.1.12.3.2 Other developments 396
13.1.13 ARTIVION, INC. 397
13.1.13.1 Business overview 397
13.1.13.2 Products offered 398
13.1.13.3 Recent developments 399
13.1.13.3.1 Other developments 399
13.1.14 STRYKER CORPORATION 400
13.1.14.1 Business overview 400
13.1.14.2 Products offered 401
13.1.15 LIFETECH SCIENTIFIC CORPORATION 402
13.1.15.1 Business overview 402
13.1.15.2 Products offered 403
13.1.16 TRANSLUMINA 404
13.1.16.1 Business overview 404
13.1.16.2 Products offered 404
13.1.17 LEPU MEDICAL TECHNOLOGY (BEIJING) CO., LTD. 406
13.1.17.1 Business overview 406
13.1.17.2 Products offered. 407
13.1.18 ENDOLOGIX LLC. 408
13.1.18.1 Business overview 408
13.1.18.2 Products offered 408
13.1.19 BIOSENSORS INTERNATIONAL GROUP, LTD. 409
13.1.19.1 Business overview 409
13.1.19.2 Products offered 409
13.1.19.3 Recent developments 410
13.1.19.3.1 Product approvals 410
13.2 OTHER PLAYERS 411
13.2.1 COOK MEDICAL 411
13.2.2 INSITU TECHNOLOGIES INC. 412
13.2.3 IVASCULAR 413
13.2.4 ORBUSNEICH MEDICAL GROUP HOLDINGS LIMITED 414
13.2.5 ALVIMEDICA 415
13.2.6 ELIXIR MEDICAL 416
14 APPENDIX 417
14.1 DISCUSSION GUIDE 417
14.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 423
14.3 CUSTOMIZATION OPTIONS 425
14.4 RELATED REPORTS 425
14.5 AUTHOR DETAILS 426